2024年PCOS Challenge-CDC利益相关者会议:女性、青春期女孩和儿童睾酮参考范围
2024年8月26日,PCOS Challenge与CDC临床标准化项目召开利益相关者会议,回顾睾酮标准化历史、性别和年龄特异性参考区间(RI)的临床需求及当前局限,提出7个领域的建议和4阶段工作计划,以建立女性、青春期女孩和儿童的睾酮RI。
要点
- 女性及儿童睾酮参考区间因实验室和检测系统差异大,影响诊断准确性。
- 会议提出7领域建议:检测标准化、参考人群表征、研究设计、数据整合、教育、全球可及性及其他生物标志物RI。
- 4阶段计划:队列识别、CDC实验室复测、统计分析、同行评审发表RI。
核心结论
- 需建立性别和年龄特异性的睾酮参考区间,以改善女性、青春期女孩和儿童雄激素相关疾病的诊疗。
研究设计与样本
- 2024年8月26日由PCOS Challenge与CDC临床标准化项目联合召开的利益相关者会议,回顾证据并形成建议。
主要发现
- 尽管睾酮检测标准化已有20年进展,儿童和成年女性参考区间仍因实验室和检测系统不同而高度可变。
- 采用CDC参考测量值归一化和合并现有队列数据的方法已验证,9个女性与青少年健康队列被确定为参考区间开发的候选队列。
- 雌二醇参考区间作为概念验证,展示了相同数据协调方法的可行性。
关键数值与推荐
- 提出7个领域建议:检测标准化、参考人群表征、研究设计参数、数据整合标准、教育推广、全球可及性、其他相关生物标志物(包括抗苗勒管激素和11-氧雄激素)的标准化参考区间需求。
- 提出4阶段工作计划:队列识别、CDC实验室标本复测、统计分析、同行评审发表参考区间。
临床怎么用
- 临床解读女性、青春期女孩和儿童睾酮结果时需考虑检测方法和参考区间的局限性。
- 关注未来标准化参考区间的发布,以用于雄激素过多症(如PCOS)和雄激素缺乏症的诊断与决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Testosterone measurement is fundamental to the management of many disorders in women, adolescent girls, and children, most notably androgen excess, including polycystic ovary syndrome (PCOS, aka polyendocrine metabolic ovarian syndrome [PMOS]) and congenital adrenal hyperplasia, and androgen deficiency disorders. Despite 2 decades of progress in testosterone assay standardization, pediatric and adult female reference intervals (RIs) remain highly variable across laboratories and assay systems, limiting diagnostic accuracy and clinical decision-making. OBJECTIVE: On August 26, 2024, PCOS Challenge: The National Polycystic Ovary Syndrome Association, in collaboration with the Centers for Disease Control and Prevention (CDC) Clinical Standardization Programs, convened a stakeholder meeting. RESULTS: Participants reviewed the historical trajectory of testosterone standardization, clinical need for sex- and age-specific RI, current RI limitations, technical challenges of measuring testosterone at female and pediatric concentrations, and a validated methodology for normalizing and combining data across existing cohorts using CDC reference measurements. Nine women's and adolescent health cohorts were identified as candidates for RI development, and an estradiol RI precedent was presented as proof of concept using the same data harmonization approach. CONCLUSION: Recommendations across 7 domains were proposed: (1) assay standardization, (2) reference population characterization, (3) study design parameters, (4) data integration standards, (5) educational outreach, (6) global access, and (7) need for standardized RI for additional relevant biomarkers, including Anti-Müllerian Hormone and 11-oxygenated androgens. A 4-phase work plan was proposed for cohort identification, specimen re-analysis at the CDC laboratory, statistical analysis, and peer-reviewed publication of the resulting RI.
引用
- Ottey S, Pokuah F, Cree MG, et al. Testosterone reference ranges in women, adolescent girls, and children: the 2024 PCOS Challenge-CDC stakeholder meeting. J Clin Endocrinol Metab. 2026. PMID: 42444555. doi:10.1210/clinem/dgag276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。